Mo1843 Parenteral Fish Oil Reverses Cholestasis in Parenteral Nutrition Associated Liver Disease

2013 ◽  
Vol 144 (5) ◽  
pp. S-1027
Author(s):  
Ryan Spurrier ◽  
Christa N. Grant ◽  
Pui Yuk Yan ◽  
Tracy Grikscheit ◽  
Russell Merritt
Author(s):  
Loris Pironi ◽  
Antonio Colecchia ◽  
Mariacristina Guidetti ◽  
Andrea Belluzzi ◽  
Antonietta D’Errico

2017 ◽  
Vol 9 (1) ◽  
pp. 21-29
Author(s):  
Jeong-A Park ◽  
Ji-Eun Park ◽  
Min-Jae Jeong ◽  
Jae-Song Kim ◽  
Eun-Sun Son ◽  
...  

Nutrients ◽  
2019 ◽  
Vol 11 (10) ◽  
pp. 2495
Author(s):  
Mikołaj Danko ◽  
Aleksandra Żyła-Pawlak ◽  
Janusz Książyk ◽  
Katarzyna Olszewska-Durkacz ◽  
Marta Sibilska ◽  
...  

Background: Deterioration of liver function, or intestinal failure-associated liver disease, is often observed in long-term parenterally fed children. Fish oil-based intravenous lipids have been reported to play a role in the prevention and treatment of intestinal failure associated liver disease. Methods: This retrospective analysis included 40 pediatric patients, (20 male and 20 female), median age 38 months (range 1.5–200 months) on long-term (≥1 month) parenteral nutrition who received the parenteral mixtures containing a combination of a third-generation lipid emulsion and pure fish oil because of laboratory liver function abnormalities. The total dose of fish oil from both emulsions for each patient exceeded 0.5 g/kg/day. Data from visits in an outpatient clinic were retrospectively analyzed using the Wilcoxon test, Mann-Whitney test, and Spearman correlation test. Results: The median time of therapy was 149 days (range 28–418 days). There was a decrease of median total and direct (conjugated) bilirubin concentration from 22.23 µmol/L (range 3.42–243 µmol/L) to 10.26 µmol/L (range 3.42–180.58 µmol/L; p < 0.005) and 8.55 (range 1.71–212.04 µmol/L) to 6.84 µmol/L (range 1.71–150.48 µmol/L; p < 0.007) respectively. A significant decrease in median alanine aminotransferase, aspartate aminotransferase and gamma-glutamyl transferase was also observed. In 11 patients bilirubin concentrations increased or remained unchanged. When compared to the patients who responded to the combination therapy, the patients who did not respond received parenteral nutrition for a longer time prior to the start of the therapy (51 vs. 30 months; p < 0.05). Conclusions: The mixture of an intravenous lipid emulsion containing soybean oil, medium-chain triglycerides, olive oil, and fish oil with the addition of pure fish oil emulsion may be helpful in the treatment of liver complications in children on long-term parenteral nutrition.


2014 ◽  
Vol 5 (1) ◽  
pp. 65-70 ◽  
Author(s):  
Muralidhar H. Premkumar ◽  
Beth A. Carter ◽  
Keli M. Hawthorne ◽  
Kristi King ◽  
Steven A. Abrams

Author(s):  
Juan Cristóbal Gana ◽  
Alex Castet ◽  
Luis A Villarroel del Pino ◽  
Lorena I Cifuentes ◽  
Romina Torres-Robles ◽  
...  

2011 ◽  
Vol 31 (5) ◽  
pp. 503-509 ◽  
Author(s):  
Emma M Tillman ◽  
Catherine M Crill ◽  
Dennis D Black ◽  
Emily B Hak ◽  
Linda F Lazar ◽  
...  

2012 ◽  
Vol 26 (5) ◽  
pp. 277-280 ◽  
Author(s):  
Ana MGA Sant’Anna ◽  
Eyad Altamimi ◽  
Rose-Frances Clause ◽  
Joanne Saab ◽  
Heather Mileski ◽  
...  

OBJECTIVE: To describe the authors’ experience with the implementation of a multidisciplinary approach and use of fish oil emulsion (FOE) in the management of infants with short bowel syndrome (SBS) and parenteral nutrition-associated liver disease (PNALD).METHODS: Between August 2006 and June 2009, four cases of SBS and severe PNALD were managed by the team using specifically developed protocols. The FOE was initiated if serum direct bilirubin levels were ≥100 μmol/L. To quantify the degree of exposure to high serum direct bilirubin levels over time, the area under the curve (AUC) for each patient was calculated before and after initiation of FOE. Linear regression analyses were performed to evaluate correlations between the AUC, duration of cholestasis and initiation of FOE.RESULTS: All patients survived and no complications were observed during the study period. After the first patient, FOE was initiated progressively earlier, but poor correlation between the AUC before and after its introduction was observed (r2=0.41924). However, there was strong correlation between the duration of PNALD before FOE initiation and time to resolution (r2=0.72133): the earlier the FOE was initiated, the shorter the time to resolution.CONCLUSION: The authors report a positive experience with the implementation of a multidisciplinary approach and the use of FOE in infants with SBS and severe PNALD. The earlier the FOE was initiated during the cholestatic process, the shorter the time to resolution. The present study is a hypothesis generator, raising the question of whether an earlier introduction of this particular therapy can effectively shorten the cholestasis process in these patients.


2010 ◽  
Vol 34 (5) ◽  
pp. 477-484 ◽  
Author(s):  
Hau D. Le ◽  
Vincent E. de Meijer ◽  
David Zurakowski ◽  
Jonathan A. Meisel ◽  
Kathleen M. Gura ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document